These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34936368)

  • 1. Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy.
    Liang S; Xu H; Ye BC
    Langmuir; 2022 Jan; 38(1):299-308. PubMed ID: 34936368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
    Chu W; Houston ZH; Fletcher NL; Huda P; Ahamed M; Lim TX; Day BW; Pinkham M; Thurecht KJ
    Biomacromolecules; 2023 Jun; 24(6):2674-2690. PubMed ID: 37143361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
    Rehman FU; Liu Y; Yang Q; Yang H; Liu R; Zhang D; Muhammad P; Liu Y; Hanif S; Ismail M; Zheng M; Shi B
    J Control Release; 2022 May; 345():696-708. PubMed ID: 35341901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactoferrin/CD133 antibody conjugated nanostructured lipid carriers for dual targeting of blood-brain-barrier and glioblastoma stem cells.
    Zhao C; Zhu X; Yang H; Tan J; Gong R; Mei C; Cai X; Su Z; Kong F
    Biomed Mater; 2024 Aug; 19(5):. PubMed ID: 39134023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3.
    Liang SF; Zuo FF; Yin BC; Ye BC
    Biomater Sci; 2022 Mar; 10(6):1582-1590. PubMed ID: 35179533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
    Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
    Wang J; Li T; Wang B
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.
    Sandbhor P; Goda J; Mohanty B; Chaudhari P; Dutt S; Banerjee R
    Nanoscale; 2021 Dec; 14(1):108-126. PubMed ID: 34897360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
    Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma.
    Jiapaer S; Furuta T; Dong Y; Kitabayashi T; Sabit H; Zhang J; Zhang G; Tanaka S; Kobayashi M; Hirao A; Nakada M
    Curr Pharm Des; 2020; 26(36):4675-4684. PubMed ID: 32348209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
    Si J; Li W; Li X; Cao L; Chen Z; Jiang Z
    Cancer Sci; 2021 Sep; 112(9):3491-3506. PubMed ID: 34036683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
    Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
    Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.